P5248
依替膦酸钠 二钠 水合物
≥97% (NMR), solid
别名:
Dihydrogen (1-hydroxyethylidene)bisphosphonate disodium hydrate
登录 查看组织和合同定价。
选择尺寸
关于此项目
经验公式（希尔记法）:
C2H6Na2O7P2 · xH2O
化学文摘社编号:
分子量:
249.99 (anhydrous basis)
NACRES:
NA.77
PubChem Substance ID:
UNSPSC Code:
12352200
EC Number:
231-025-7
MDL number:
InChI key
GWBBVOVXJZATQQ-UHFFFAOYSA-L
InChI
1S/C2H8O7P2.2Na/c1-2(3,10(4,5)6)11(7,8)9;;/h3H,1H3,(H2,4,5,6)(H2,7,8,9);;/q;2*+1/p-2
SMILES string
[Na+].[Na+].CC(O)(P(O)([O-])=O)P(O)([O-])=O
assay
≥97% (NMR)
form
solid
color
white
mp
>300 °C
solubility
H2O: ≥10 mg/mL
storage temp.
2-8°C
Quality Level
相关类别
Application
Etidronate disodium hydrate has been used in the synthesis of bisphosphonate derivatives of adenosine triphosphate (ATP)by T4 RNA ligase. It has also been sued to inhibit human farnesyl diphosphate synthase (FDPS).
Biochem/physiol Actions
Bisphosphonate antiresorptive agent. Less potent inhibitor of farnesyl diphosphate synthase (IC50 = 80 μM) as compared to the nitrogen containing bisphosphonates
Etidronate helps to guard chronic ocular hypertension prompted retinal oxidative stress. It stimulates the development of retinal ganglion cells through insulin-like growth factor 1 (IGF-1) signaling pathway. It may possess neuroprotective effects in in vivo and in vitro rat model of glaucoma. Etidronate belongs to bisphosphonates.
signalword
Warning
hcodes
Hazard Classifications
Acute Tox. 4 Oral
存储类别
11 - Combustible Solids
wgk
WGK 1
flash_point_f
Not applicable
flash_point_c
Not applicable
ppe
dust mask type N95 (US), Eyeshields, Gloves
Etidronate protects chronic ocular hypertension induced retinal oxidative stress and promotes retinal ganglion cells growth through IGF-1 signaling pathway
Su J and Huang M
European Journal of Pharmacology, 841, 75-81 (2018)
Synthesis of bisphosphonate derivatives of ATP by T4 RNA ligase
Sillero M A G, et al.
Febs Letters, 580(24), 5723-5727 (2006)
M R McClung et al.
Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA, 24(1), 301-310 (2012-10-20)
Bone mineral density response to once weekly delayed-release formulation of risedronate, given before or following breakfast, was non-inferior to that seen with traditional immediate-release risedronate given daily before breakfast. Delayed-release risedronate is a convenient dosing regimen for oral bisphosphonate therapy
Nicole C Ferko et al.
Managed care (Langhorne, Pa.), 21(11), 44-52 (2012-12-15)
Because of rising drug expenditures, cost considerations have become essential, necessitating the requirement for cost-effectiveness analyses for managed care organizations (MCOs). The study objective is to examine the impact of various drug-cost components, in addition to wholesale acquisition cost (WAC)
Siyoung Kim et al.
European journal of pharmacology, 699(1-3), 14-22 (2012-12-04)
Nitrogen-containing bisphosphonates (NBPs) have greater anti-bone-resorptive effects than non-nitrogen-containing bisphosphonates (non-NBPs). Hence, NBPs are the current first-choice drug for osteoporosis. However, NBPs carry a risk of osteonecrosis of jaws. Some animal and human studies suggest that non-NBPs may have anti-bone-resorptive
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持